Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
| ▸ | INPPL1 | O15357 | 7/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581742 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL2419732 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30236403 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30005568 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30005904 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30509670 | 1.00 | MET (0.44) | METSRCKDRKITFGFR2 | |
| SCHEMBL30765076 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL1582536 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL488432 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 | |
| SCHEMBL28018826 | 0.89 | MET (0.36) | METSRCKDRKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082110-B | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2024-04-12 | — | — | CN | claimed |
| CN-115448813-B | Method for preparing (S) -2, 6-dichloro-3-fluorophenylethanol | 中国科学院兰州化学物理研究所 | 2023-07-25 | — | — | CN | claimed |
| CN-116082110-A | The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof | 北京肿瘤医院(北京大学肿瘤医院) | 2023-05-09 | — | — | CN | claimed |
| CN-108285908-B | Method for catalytic synthesis of (S) -1- (2, 6-dichloro-3-fluoro-phenyl) ethanol by using immobilized double enzymes | 杭州师范大学 | 2021-02-09 | — | — | CN | claimed |
| CN-111118072-A | Method for preparing enzatinib intermediate by enzyme method | 长兴制药股份有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-109942485-A | A kind of gram of azoles replaces the synthetic method of Buddhist nun's intermediate | 青岛前线生物工程有限公司 | 2019-06-28 | — | — | CN | claimed |
| CN-109438180-A | The preparation method of one kind (S) -1- (the chloro- 3- fluorophenyl of 2,6- bis-) ethyl alcohol | 凯瑞斯德生化(苏州)有限公司 | 2019-03-08 | — | — | CN | claimed |
| CN-108285908-A | A kind of method that immobilized bi-enzyme catalyzes and synthesizes (S) -1- (bis- chloro- 3- fluoro-phenyls of 2,6-) ethyl alcohol | 杭州师范大学 | 2018-07-17 | — | — | CN | claimed |
| CN-107794282-A | A kind of gram of azoles replaces the preparation method and bacterial strain of Buddhist nun's chiral intermediate | 浙江工业大学 | 2018-03-13 | — | — | CN | claimed |
| CN-106047950-A | Biological preparation method of (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol | 尚科生物医药（上海）有限公司 | 2016-10-26 | — | — | CN | claimed |
| CN-105906656-A | Synthetic method of crizotinib intermediate | 凯莱英医药集团（天津）股份有限公司 | 2016-08-31 | — | — | CN | claimed |
| EP-2198018-A2 | KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES | Codexis, Inc. (US) | 2010-06-23 | — | — | EP | claimed |
| WO-2009036404-A2 | KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES | CODEXIS, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| EP-1791965-A1 | ENANTIOSELECTIVE BIOTRANSFORMATION FOR PREPARATION OF PROTEIN TYROSINE KINASE INHIBITOR INTERMEDIATES | Pfizer, Inc. (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006021885-A1 | ENANTIOSELECTIVE BIOTRANSFORMATION FOR PREPARATION OF PROTEIN TYROSINE KINASE INHIBITOR INTERMEDIATES | PFIZER INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060046287-A1 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | claimed |
| US-12415990-B2 | Ketoreductase polypeptides for the reduction of acetophenones | CODEXIS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| CN-116496140-B | Preparation method of tenidine drug intermediate | 凯特立斯（深圳）科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885SRC 76/4885KDR 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.